A Study of BGM0504 Tablets in Healthy and Non-diabetic Overweight or Obese Chinese Subjects

StatusCompleted
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial completed Show 4 more changesShow less
    • Primary and study completion dates changed from estimate of Mar 31, 2026 to Mar 5, 2026
    • Start date: Oct 21, 2025 to Oct 24, 2025
    • Site details revised
    • Eligibility criteria expanded, about 1 word
  2. Study First Submitted
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A Randomized, Double-Blind, Placebo-Controlled, Single/Multiple-dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BGM0504 Tablets Orally Administered in Healthy and Non-diabetic Overweight or Obese Chinese Subjects.
Trial Details
NCT Number NCT07239973
Lead Sponsor BrightGene Bio-Medical Technology Co., Ltd.
Conditions
(from sponsor)		 Healthy, Non-diabetic Overweight or Obese
Related terms Obesity
Enrollment 75 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov